Brokerages forecast that Inogen (NASDAQ:INGN) will report earnings of $0.27 per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Inogen’s earnings, with estimates ranging from $0.17 to $0.35. Inogen also reported earnings of $0.27 per share during the same quarter last year. The company is expected to report its next earnings results on Tuesday, May 8th.
On average, analysts expect that Inogen will report full year earnings of $1.60 per share for the current year, with EPS estimates ranging from $1.41 to $1.68. For the next year, analysts expect that the firm will report earnings of $1.76 per share, with EPS estimates ranging from $1.59 to $1.90. Zacks’ EPS calculations are an average based on a survey of analysts that cover Inogen.
Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.10. Inogen had a net margin of 8.42% and a return on equity of 13.47%. The business had revenue of $63.79 million for the quarter, compared to analysts’ expectations of $62.01 million.
Several analysts have commented on INGN shares. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $132.00 price objective on the stock in a research report on Tuesday, February 6th. Piper Jaffray raised shares of Inogen from a “neutral” rating to an “overweight” rating in a research report on Tuesday, February 20th. BidaskClub lowered shares of Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Inogen in a research report on Tuesday, March 27th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $121.17.
Inogen stock opened at $139.25 on Friday. The stock has a market cap of $3,012.78, a P/E ratio of 107.81, a PEG ratio of 3.95 and a beta of 1.03. Inogen has a fifty-two week low of $76.42 and a fifty-two week high of $144.05.
In related news, Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 17th. The shares were sold at an average price of $139.82, for a total transaction of $139,820.00. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at approximately $139,820. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Alison Bauerlein sold 11,718 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $115.87, for a total transaction of $1,357,764.66. Following the sale, the chief financial officer now directly owns 11,718 shares in the company, valued at approximately $1,357,764.66. The disclosure for this sale can be found here. In the last three months, insiders sold 115,718 shares of company stock worth $14,059,611. Insiders own 5.29% of the company’s stock.
A number of institutional investors have recently bought and sold shares of INGN. BlackRock Inc. increased its holdings in Inogen by 4.0% during the 4th quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock worth $274,662,000 after acquiring an additional 87,737 shares during the period. Rock Springs Capital Management LP bought a new stake in Inogen during the 4th quarter worth approximately $9,526,000. Fuller & Thaler Asset Management Inc. bought a new stake in Inogen during the 4th quarter worth approximately $8,858,000. WINTON GROUP Ltd bought a new stake in Inogen during the 4th quarter worth approximately $5,874,000. Finally, Renaissance Technologies LLC increased its holdings in Inogen by 27.3% during the 4th quarter. Renaissance Technologies LLC now owns 198,736 shares of the medical technology company’s stock worth $23,665,000 after acquiring an additional 42,636 shares during the period. 98.97% of the stock is currently owned by institutional investors and hedge funds.
WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/20/inogen-ingn-expected-to-announce-earnings-of-0-27-per-share.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Get a free copy of the Zacks research report on Inogen (INGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.